Trial Profile
Long-term effects of Natalizumab in a French cohort of patients with relapsing-remitting multiple sclerosis (RRMS): TYSTEN cohort
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms TYSTEN
- 26 Oct 2018 New trial record
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis